­­­­­­­­­Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at ASCO 2020 Annual Meeting

Author's Avatar
May 14, 2020
Article's Main Image

PR Newswire